Tags

Type your tag names separated by a space and hit enter

Clinical trial: multispecies probiotic supplementation alleviates the symptoms of irritable bowel syndrome and stabilizes intestinal microbiota.
Aliment Pharmacol Ther 2008; 27(1):48-57AP

Abstract

BACKGROUND

Irritable bowel syndrome is the most common diagnosis in gastroenterology. Trials suggest certain probiotics to be beneficial.

AIM

To investigate the effects of multispecies probiotic supplementation (Lactobacillus rhamnosus GG, L. rhamnosus Lc705, Propionibacterium freudenreichii ssp. shermanii JS and Bifidobacterium animalis ssp. lactis Bb12) on abdominal symptoms, quality of life, intestinal microbiota and inflammatory markers in irritable bowel syndrome.

METHODS

Eighty-six irritable bowel syndrome patients (Rome II criteria) participated in this randomized, placebo-controlled 5-month intervention. Patients were randomized to receive daily either multispecies probiotic supplementation or placebo. Irritable bowel syndrome symptoms, quality of life, microarray-based intestinal microbiota stability (n = 20), serum cytokines and sensitive C-reactive protein were monitored.

RESULTS

The composite irritable bowel syndrome score had at 5 months decreased 14 points (95% CI: -19 to -9) from baseline with the multispecies probiotic vs. three points (95% CI: -8 to 1) with placebo (P = 0.0083). Especially, distension and abdominal pain were affected. A stabilization of the microbiota was observed, as the microbiota similarity index increased with the probiotic supplementation (1.9 +/- 3.1), while it decreased with placebo (-2.9 +/- 1.7). No differences were seen in C-reactive protein.

CONCLUSIONS

This multispecies probiotic seems to be an effective and safe option to alleviate symptoms of irritable bowel syndrome, and to stabilize the intestinal microbiota.

Authors+Show Affiliations

Institute of Biomedicine, Pharmacology, University of Helsinki, Helsinki, Finland.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

17919270

Citation

Kajander, K, et al. "Clinical Trial: Multispecies Probiotic Supplementation Alleviates the Symptoms of Irritable Bowel Syndrome and Stabilizes Intestinal Microbiota." Alimentary Pharmacology & Therapeutics, vol. 27, no. 1, 2008, pp. 48-57.
Kajander K, Myllyluoma E, Rajilić-Stojanović M, et al. Clinical trial: multispecies probiotic supplementation alleviates the symptoms of irritable bowel syndrome and stabilizes intestinal microbiota. Aliment Pharmacol Ther. 2008;27(1):48-57.
Kajander, K., Myllyluoma, E., Rajilić-Stojanović, M., Kyrönpalo, S., Rasmussen, M., Järvenpää, S., ... Korpela, R. (2008). Clinical trial: multispecies probiotic supplementation alleviates the symptoms of irritable bowel syndrome and stabilizes intestinal microbiota. Alimentary Pharmacology & Therapeutics, 27(1), pp. 48-57.
Kajander K, et al. Clinical Trial: Multispecies Probiotic Supplementation Alleviates the Symptoms of Irritable Bowel Syndrome and Stabilizes Intestinal Microbiota. Aliment Pharmacol Ther. 2008 Jan 1;27(1):48-57. PubMed PMID: 17919270.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Clinical trial: multispecies probiotic supplementation alleviates the symptoms of irritable bowel syndrome and stabilizes intestinal microbiota. AU - Kajander,K, AU - Myllyluoma,E, AU - Rajilić-Stojanović,M, AU - Kyrönpalo,S, AU - Rasmussen,M, AU - Järvenpää,S, AU - Zoetendal,E G, AU - de Vos,W M, AU - Vapaatalo,H, AU - Korpela,R, Y1 - 2007/10/05/ PY - 2007/10/9/pubmed PY - 2008/1/10/medline PY - 2007/10/9/entrez SP - 48 EP - 57 JF - Alimentary pharmacology & therapeutics JO - Aliment. Pharmacol. Ther. VL - 27 IS - 1 N2 - BACKGROUND: Irritable bowel syndrome is the most common diagnosis in gastroenterology. Trials suggest certain probiotics to be beneficial. AIM: To investigate the effects of multispecies probiotic supplementation (Lactobacillus rhamnosus GG, L. rhamnosus Lc705, Propionibacterium freudenreichii ssp. shermanii JS and Bifidobacterium animalis ssp. lactis Bb12) on abdominal symptoms, quality of life, intestinal microbiota and inflammatory markers in irritable bowel syndrome. METHODS: Eighty-six irritable bowel syndrome patients (Rome II criteria) participated in this randomized, placebo-controlled 5-month intervention. Patients were randomized to receive daily either multispecies probiotic supplementation or placebo. Irritable bowel syndrome symptoms, quality of life, microarray-based intestinal microbiota stability (n = 20), serum cytokines and sensitive C-reactive protein were monitored. RESULTS: The composite irritable bowel syndrome score had at 5 months decreased 14 points (95% CI: -19 to -9) from baseline with the multispecies probiotic vs. three points (95% CI: -8 to 1) with placebo (P = 0.0083). Especially, distension and abdominal pain were affected. A stabilization of the microbiota was observed, as the microbiota similarity index increased with the probiotic supplementation (1.9 +/- 3.1), while it decreased with placebo (-2.9 +/- 1.7). No differences were seen in C-reactive protein. CONCLUSIONS: This multispecies probiotic seems to be an effective and safe option to alleviate symptoms of irritable bowel syndrome, and to stabilize the intestinal microbiota. SN - 1365-2036 UR - https://www.unboundmedicine.com/medline/citation/17919270/Clinical_trial:_multispecies_probiotic_supplementation_alleviates_the_symptoms_of_irritable_bowel_syndrome_and_stabilizes_intestinal_microbiota_ L2 - https://doi.org/10.1111/j.1365-2036.2007.03542.x DB - PRIME DP - Unbound Medicine ER -